Zoetis (ZTS) Tops Q4 EPS by 4c; Affirms FY16 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Zoetis' (ZTS) Simparica Should Gain Approval in March - Piper Jaffray
February 17, 2016 8:19 AM ESTDespite reducing Zoetis Inc. (NYSE: ZTS) price target by 9%, Piper Jaffray analyst, Kevin Ellich kept his Outperform rating and sees a near term catalyst as Simparica prepares for launch and Apoquel finds a second API source.
ZTS reported solid Q4 results highlighted by 6% operational growth which included 30% operational growth in U.S. companion animal product sales. Revenue beat Street estimates even with... More
